Search

Displaying results 5961 - 5970 of 7687 in total
  1. Drug

    Adipiplon

    go.drugbank.com/drugs/DB06579
    Investigational

    Adipiplon is an nonbenzodiazepine anxiolytic developed by Neurogen Corporation. It is known by the standardized identifier NG2-73.

  2. Drug

    Sparsomycin

    go.drugbank.com/drugs/DB04222
    Experimental

    An antitumor antibiotic produced by Streptomyces sparsogenes. It inhibits protein synthesis in 70S and 80S ribosomal systems. [PubChem]

  3. Drug

    Nordazepam

    go.drugbank.com/drugs/DB14028
    Investigational

    An intermediate in the metabolism of DIAZEPAM to OXAZEPAM. It may have actions similar to those of diazepam.

  4. Drug

    Autologous DNP-conjugated tumour vaccine

    go.drugbank.com/drugs/DB17361
    Investigational

    Autologous DNP-conjugated tumour vaccine, or melanoma vaccine, is an investigational autologous cell vaccine technology for melanoma.[A254806]

  5. Drug

    Trotabresib

    go.drugbank.com/drugs/DB17421
    Investigational

    Trotabresib is an oral, potent, and reversible inhibitor of the epigenetic target bromodomain and extra-terminal (BET) proteins.

  6. Drug

    OPC1

    go.drugbank.com/drugs/DB17944
    Experimental

    OPC1 is an oligodendrocyte progenitor cell therapy being investigated for the treatment of acute spinal cord injury.[L47082]

  7. Drug

    NGN-101

    go.drugbank.com/drugs/DB18335
    Investigational

    NGN-101 is an adeno-associated virus serotype 9 vector with engineered transgene encoding the human CLN5 gene

  8. Drug

    ECT204

    go.drugbank.com/drugs/DB18605
    Investigational

    ECT204 is an autologous T-cell therapy whereby T cells are genetically modified to target tumor-specific antigens.

  9. Drug

    Prosetin

    go.drugbank.com/drugs/DB18649
    Investigational

    Prosetin is an orally administered blocker of MAP4K under investigation for the treatment of amyotrophic lateral sclerosis.[L48360]

  10. Drug

    Rovaleucel

    go.drugbank.com/drugs/DB18691
    Investigational

    Rovaleucel is an EBV-specific autologous T-cell therapy under investigation for the treatment of EBV-positive cancers.